Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.164.275 |
Chemical and physical data | |
Formula | C12H13Cl2N3 |
Molar mass | 270.16 g·mol−1 |
3D model (JSmol) |
|
SMILES
| |
InChI
| |
(what is this?) (verify) |
Alinidine (ST567) is a negative chronotrope that was developed in the 1970s and 1980s. It causes bradycardia by inhibiting the pacemaker current by altering the maximal channel conductance and alter the voltage threshold.[1] The development of alinidine was halted because it was not sufficiently specific for its target. It also has a blocking effect on calcium channels and potassium channels. It also causes elongation of re-polarisation after an action potential.[2]
Alinidine did not improve outcomes among patients with acute myocardial infarction in a randomized controlled trial.[3]